Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia

Halla S. Nimeiri, Amit M. Oza, Robert J. Morgan, Gregory Friberg, Kristen Kasza, Leonardo Faoro, Ravi Salgia, Walter M. Stadler, Everett E. Vokes, Gini F. Fleming*

*Corresponding author for this work

Research output: Contribution to journalArticle

126 Scopus citations

Abstract

Objectives: The objectives of this phase II trial were to assess the activity and tolerability of the combination of bevacizumab and erlotinib in patients with recurrent ovarian, primary peritoneal or fallopian tube cancer. Methods: This was a single arm, multicenter phase II trial with overall objective response as the primary endpoint. Eligible patients had two or fewer prior chemotherapy regimens for recurrent or refractory disease and no prior anti-VEGF or anti-EGFR agents. Bevacizumab, 15 mg/kg, was administered intravenously every 21 days and erlotinib, 150 mg orally, was given daily. Results: Between July and October 2005, 13 patients were enrolled. There were two major objective responses, one complete response of 16+ month duration and one partial response of 11 month duration, for a response rate of 15% (95% CI 1.9% to 45.4%). Seven patients had a best response of stable disease. The most common grade 3 or 4 toxicities included anemia (n = 1), nausea (n = 2), vomiting (n = 1), hypertension (n = 1), and diarrhea (n = 2). One patient with an ileostomy was removed from the study secondary to grade 3 diarrhea. Two patients had fatal gastrointestinal perforations. Conclusion: There was no strong suggestion that this combination was superior to single agent bevacizumab, and the rate of gastrointestinal perforation was of concern. The study was therefore stopped. Identification of risk factors for gastrointestinal perforation will be of importance for the use of bevacizumab in the treatment of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalGynecologic Oncology
Volume110
Issue number1
DOIs
StatePublished - Jul 1 2008

Keywords

  • Bevacizumab
  • Erlotinib
  • Ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Fingerprint Dive into the research topics of 'Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia'. Together they form a unique fingerprint.

  • Cite this